

Monthly Corporate Action Tracker

Dossier of key corporate actions in November, 2022

Research Analyst

Raj Deepak Singh rajdeepak.singh@icicisecurities.com

Bharat Chhoda bharat.chhoda@icicisecurities.com Cheragh Sidhwa cheragh.sidhwa@icicisecurities.com







Announced dividend					
Company	Dividend	Face value		Dividend Yield	Ex-date
	(%)	(₹)	(₹/share)	(%)	
Coal India	150.0	10.0	15.0	6.0	15-11-2022
P & G Health Ltd	115.0	10.0	11.5	0.3	15-11-2022
Gillette India	360.0	10.0	36.0	0.7	10-11-2022
Siyaram Silk	200.0	2.0	4.0	0.7	11-11-2022
GMM Pfaudler	50.0	2.0	1.0	0.1	11-11-2022
Jamna Auto Inds.	80.0	1.0	0.8	0.7	14-11-2022
Amara Raja Batt.	290.0	1.0	2.9	0.5	15-11-2022
Nicco Parks	40.0	1.0	0.4	0.4	14-11-2022
Ajanta Pharma	350.0	2.0	7.0	0.6	11-11-2022
Bhagiradha Chem.	10.0	10.0	1.0	0.1	16-11-2022
Tech Mahindra	360.0	5.0	18.0	1.7	09-11-2022
L T Foods	50.0	1.0	0.5	0.4	10-11-2022
Cams Services	85.0	10.0	8.5	0.3	16-11-2022
Global Education	30.0	5.0	1.5	0.7	25-11-2022
Share India Sec.	20.0	10.0	2.0	0.1	10-11-2022
Varanium Cloud	10.0	10.0	1.0	0.3	10-11-2022





	Board meetings in	November 2022
Company name	Meeting date	Board meeting purpose
Godrej Consumer	08-11-2022	Quarterly Results
P I Industries	08-11-2022	Quarterly Results
Bosch	08-11-2022	Quarterly Results
Jubilant Food.	08-11-2022	Quarterly Results
MRF	08-11-2022	terly Results, Interim Dividend, Private Placement E
Honeywell Auto	08-11-2022	Quarterly Results
Phoenix Mills	08-11-2022	Quarterly Results
Dr Lal Pathlabs	08-11-2022	Quarterly Results
Sundram Fasten.	08-11-2022	Quarterly Results
Piramal Pharma	08-11-2022	Quarterly Results
Aptus Value Hou.	08-11-2022	Quarterly Results
Sheela Foam	08-11-2022	Quarterly Results, Bonus Issue
Bajaj Electrical	08-11-2022	Quarterly Results
Chola Financial	08-11-2022	Quarterly Results
Suven Pharma	08-11-2022	Quarterly Results
Aegis Logistics	08-11-2022	Quarterly Results, Interim Dividend
Metropolis Healt	08-11-2022	Quarterly Results
Laxmi Organic	08-11-2022	Quarterly Results
Welspun India	08-11-2022	Quarterly Results
Birla Corpn.	08-11-2022	Quarterly Results
VST Industries	08-11-2022	Quarterly Results
Hindustan Foods	08-11-2022	Quarterly Results
Greenpanel Inds.	08-11-2022	Quarterly Results
NCC	08-11-2022	Quarterly Results
Usha Martin	08-11-2022	Quarterly Results
NOCIL	08-11-2022	Quarterly Results
Tata Motors	09-11-2022	Quarterly Results
Pidilite Inds.	09-11-2022	Quarterly Results
Star Health Insu	09-11-2022	Quarterly Results
Godrej Propert.	09-11-2022	Quarterly Results

Source: Capitaline, ICICI Direct Research

Company name	Meeting date	Board meeting purpose	
Lupin	09-11-2022	Quarterly Results	
Deepak Nitrite	09-11-2022	Quarterly Results	
Petronet LNG	09-11-2022	Quarterly Results, Interim Dividend	
APL Apollo Tubes	09-11-2022	Quarterly Results	
3M India	09-11-2022	Quarterly Results, Interim Dividend	
General Insuranc	09-11-2022	Quarterly Results	
Piramal Enterp.	09-11-2022	Quarterly Results	
Bayer Crop Sci.	09-11-2022	Quarterly Results, Interim Dividend	
Prestige Estates	09-11-2022	Quarterly Results	
The Ramco Cement	09-11-2022	Quarterly Results	
Narayana Hrudaya	09-11-2022	Quarterly Results	
Nuvoco Vistas	09-11-2022	Accounts, Quarterly Results	
Natl. Aluminium	09-11-2022	Quarterly Results	
Powergrid Infra.	09-11-2022	Quarterly Results, Dividend	
Westlife Develop	09-11-2022	Quarterly Results	
Tata Motors-DVR	09-11-2022	Quarterly Results	
KIOCL	09-11-2022	Quarterly Results	
RHI Magnesita	09-11-2022	Quarterly Results	
Allcargo Logist.	09-11-2022	Quarterly Results	
Galaxy Surfact.	09-11-2022	Quarterly Results	
Finolex Cables	09-11-2022	Quarterly Results	
Quess Corp	09-11-2022	Quarterly Results, Interim Dividend	
Shyam Metalics	09-11-2022	Quarterly Results	
Borosil Renew.	09-11-2022	Quarterly Results	
Balrampur Chini	09-11-2022	Quarterly Results, Buy Back	
Gujarat Alkalies	09-11-2022	Quarterly Results	
BEML Ltd	09-11-2022	Quarterly Results	
Prince Pipes	09-11-2022	Quarterly Results	
Edelweiss.Fin.	09-11-2022	Quarterly Results	
Rolex Rings	09-11-2022	Quarterly Results	



Board meetings in November 2022			
Company name	Meeting date	Board meeting purpose	
GSFC	09-11-2022	Quarterly Results	
Team Lease Serv.	09-11-2022	Quarterly Results	
HLE Glascoat	09-11-2022	Quarterly Results	
Barbeque-Nation	09-11-2022	Quarterly Results	
Guj Pipavav Port	09-11-2022	Quarterly Results, Interim Dividend	
Hikal	09-11-2022	Quarterly Results	
Engineers India	09-11-2022	Quarterly Results	
Adani Green	10-11-2022	Quarterly Results	
Eicher Motors	10-11-2022	Quarterly Results	
Apollo Hospitals	10-11-2022	Quarterly Results	
Berger Paints	10-11-2022	Quarterly Results	
Page Industries	10-11-2022	Quarterly Results, Interim Dividend	
Zomato Ltd	10-11-2022	Quarterly Results	
Trent	10-11-2022	Quarterly Results	
Jindal Steel	10-11-2022	Quarterly Results	
Container Corpn.	10-11-2022	Interim Dividend, Quarterly Results	
ndian Hotels Co	10-11-2022	Quarterly Results	
Samvardh. Mothe.	10-11-2022	Quarterly Results	
NHPC Ltd	10-11-2022	Quarterly Results	
Muthoot Finance	10-11-2022	Quarterly Results	
Ashok Leyland	10-11-2022	Quarterly Results	
Gujarat Gas	10-11-2022	Quarterly Results	
SAIL	10-11-2022	Quarterly Results	
RFC	10-11-2022	Quarterly Results,Interim Dividend	
Jno Minda	10-11-2022	Quarterly Results	
Power Fin.Corpn.	10-11-2022	Quarterly Results	
_inde India	10-11-2022	Quarterly Results	
Torrent Power	10-11-2022	Quarterly Results	
Bata India	10-11-2022	Quarterly Results	
Oil India	10-11-2022	Quarterly Results, Interim Dividend	

Source: Capitaline, ICICI Direct Research

Board meetings in November 2022			
Company name	Meeting date	Board meeting purpose	
Fine Organic	10-11-2022	Quarterly Results	
Campus Activewe.	10-11-2022	Quarterly Results	
Mazagon Dock	10-11-2022	Quarterly Results, Interim Dividend	
Ratnamani Metals	10-11-2022	Quarterly Results	
Aster DM Health.	10-11-2022	Quarterly Results	
Century Plyboard	10-11-2022	Quarterly Results	
Guj.St.Petronet	10-11-2022	Quarterly Results	
Sh.Renuka Sugar	10-11-2022	Quarterly Results	
BASF India	10-11-2022	Quarterly Results	
G R Infraproject	10-11-2022	Quarterly Results, Interim Dividend	
Deepak Fertiliz.	10-11-2022	Quarterly Results	
Natco Pharma	10-11-2022	Quarterly Results, Interim Dividend	
Zydus Wellness	10-11-2022	Quarterly Results	
GNFC	10-11-2022	Quarterly Results	
Kalyan Jewellers	10-11-2022	Quarterly Results	
India Grid Trust	10-11-2022	Quarterly Results, Raising funds through Debt Inst	
Suzlon Energy	10-11-2022	Quarterly Results	
Rites	10-11-2022	Quarterly Results, Interim Dividend	
Rail Vikas	10-11-2022	Quarterly Results	
Cochin Shipyard	10-11-2022	Quarterly Results, Interim Dividend	
Kalpataru Power	10-11-2022	Quarterly Results	
eClerx Services	10-11-2022	Quarterly Results, Buy Back	
RattanIndia Ent	10-11-2022	Quarterly Results	
Prism Johnson	10-11-2022	Quarterly Results	
India Infr Trust	10-11-2022	Half Yearly Results	
Avanti Feeds	10-11-2022	Quarterly Results	
Garden Reach Sh.	10-11-2022	Quarterly Results	
Sunteck Realty	10-11-2022	Quarterly Results	
Reliance Power	10-11-2022	Quarterly Results	
Kennametal India	10-11-2022	Quarterly Results	



Board meetings in November 2022

Company name	Meeting date	Board meeting purpose
VRL Logistics	10-11-2022	Quarterly Results
Vijaya Diagnost.	10-11-2022	Quarterly Results
Health.Global	10-11-2022	Quarterly Results
NESCO	10-11-2022	Quarterly Results
Paisalo Digital	10-11-2022	Quarterly Results
Railtel Corpn.	10-11-2022	Quarterly Results
Life Insurance	11-11-2022	Quarterly Results
M & M	11-11-2022	Quarterly Results
Adani Power	11-11-2022	Quarterly Results
Hindalco Inds.	11-11-2022	Quarterly Results
Hind. Aeronautics	11-11-2022	Accounts,Interim Dividend
ABB	11-11-2022	Quarterly Results
Info Edg.(India)	11-11-2022	Quarterly Results
Zydus Lifesci.	11-11-2022	Quarterly Results
Astral	11-11-2022	Quarterly Results,Interim Dividend
Alkem Lab	11-11-2022	Quarterly Results
Vedant Fashions	11-11-2022	Quarterly Results
Delhivery	11-11-2022	Quarterly Results
Thermax	11-11-2022	Quarterly Results
BHEL	11-11-2022	Quarterly Results
Zee Entertainmen	11-11-2022	Quarterly Results
lpca Labs.	11-11-2022	Quarterly Results, Interim Dividend
Glaxosmi. Pharma	11-11-2022	Quarterly Results, Change in Directors
Sun TV Network	11-11-2022	Quarterly Results,Interim Dividend
Fortis Health.	11-11-2022	Quarterly Results
Emami	11-11-2022	Quarterly Results, Interim Dividend
Pfizer	11-11-2022	Quarterly Results
Bharat Dynamics	11-11-2022	Quarterly Results
New India Assura	11-11-2022	Quarterly Results
J B Chem & Pharm	11-11-2022	Quarterly Results

Source: Capitaline, ICICI Direct Research

	Board meetings in November 2022			
Company name	Meeting date	Board meeting purpose		
Exide Inds.	11-11-2022	Quarterly Results		
SJVN	11-11-2022	Quarterly Results		
Alembic Pharma	11-11-2022	Quarterly Results		
IDFC	11-11-2022	Quarterly Results		
Glenmark Pharma.	11-11-2022	Quarterly Results		
Aether Industri.	11-11-2022	Quarterly Results		
Krishna Institu.	11-11-2022	Quarterly Results		
EID Parry	11-11-2022	Quarterly Results		
NLC India	11-11-2022	Quarterly Results		
ΙΤΙ	11-11-2022	Quarterly Results		
KRBL	11-11-2022	Quarterly Results		
Mahanagar Gas	11-11-2022	Quarterly Results		
Astrazeneca Phar	11-11-2022	Quarterly Results		
Easy Trip Plann.	11-11-2022	Quarterly Results		
FACT	11-11-2022	Quarterly Results		
GE Shipping Co	11-11-2022	Quarterly Results, Interim Dividend		
Lemon Tree Hotel	11-11-2022	Quarterly Results		
Medplus Health	11-11-2022	Quarterly Results		
Graphite India	11-11-2022	Quarterly Results		
P & G Health Ltd	11-11-2022	Quarterly Results		
Ingersoll-Rand	11-11-2022	Quarterly Results, Interim Dividend		
Restaurant Brand	11-11-2022	Quarterly Results		
Sobha	11-11-2022	Quarterly Results		
V-Mart Retail	11-11-2022	Quarterly Results		
Guj. Ambuja Exp	11-11-2022	Quarterly Results		
Religare Enterp.	11-11-2022	Quarterly Results		
Esab India	11-11-2022	Quarterly Results, Interim Dividend		
Borosil	11-11-2022	Quarterly Results		
Ircon Intl.	11-11-2022	Quarterly Results		
La Opala RG	11-11-2022	uarterly Results, Interim Dividend, Delisting of Share		



Во	oard meetings in N	November 2022
Company name	Meeting date	Board meeting purpose
Indbull.RealEst.	11-11-2022	Quarterly Results
HEG	11-11-2022	Quarterly Results
Patanjali Foods	12-11-2022	Quarterly Results
Aurobindo Pharma	12-11-2022	Quarterly Results
J K Cements	12-11-2022	Quarterly Results
Trident	12-11-2022	Quarterly Results
Brigade Enterpr.	12-11-2022	Quarterly Results
Hindustan Copper	12-11-2022	Quarterly Results
Manappuram Fin.	12-11-2022	Quarterly Results, Interim Dividend
Godfrey Phillips	12-11-2022	Quarterly Results
Brightcom Group	12-11-2022	Quarterly Results
Bombay Burmah	12-11-2022	Quarterly Results
R C F	12-11-2022	Quarterly Results
Caplin Point Lab	12-11-2022	Quarterly Results
Greenlam Industr	12-11-2022	Quarterly Results
Kirloskar Oil	12-11-2022	Quarterly Results
O N G C	14-11-2022	Quarterly Results, Interim Dividend
Grasim Inds	14-11-2022	Quarterly Results
IRCTC	14-11-2022	Quarterly Results
Abbott India	14-11-2022	Quarterly Results
Bharat Forge	14-11-2022	Quarterly Results
Biocon	14-11-2022	Quarterly Results

Source: Capitaline, ICICI Direct Research

Company name	Meeting date	Board meeting purpose	
Aarti Industries	14-11-2022	Quarterly Results, Accounts	
AIA Engineering	14-11-2022	Quarterly Results	
GMR Airports Inf	14-11-2022	Others	
Mindspace Busine	14-11-2022	Quarterly Results	
Godrej Industrie	14-11-2022	Quarterly Results	
Radico Khaitan	14-11-2022	Others	
CESC	14-11-2022	Quarterly Results	
HUDCO	14-11-2022	Quarterly Results	
Jyothy Labs	14-11-2022	Quarterly Results	
JM Financial	14-11-2022	Quarterly Results	
PNC Infratech	14-11-2022	Quarterly Results	
Jindal Worldwide	14-11-2022	Others	
NBCC	14-11-2022	Quarterly Results	
Polyplex Corpn	14-11-2022	Others	
Swan Energy	14-11-2022	Quarterly Results	
Lux Industries	14-11-2022	Quarterly Results	
FDC	14-11-2022	Quarterly Results	
Syrma SGS Tech.	14-11-2022	Quarterly Results	
Uflex	14-11-2022	Quarterly Results	
Mishra Dhatu Nig	14-11-2022	Quarterly Results	
Suprajit Engg.	14-11-2022	Quarterly Results	
Varroc Engineer	14-11-2022	Quarterly Results	
Star Cement	14-11-2022	Others	







Stock split				
Company Name	Ratio	split	split	Record date
Steel Str. Wheel	1:5	5.0	1.0	11-11-2022
Arfin India	1:10	10.0	1.0	14-11-2022
Mafatlal Inds.	1:5	10.0	2.0	NA
Supreme Petroch.	1:2	4.0	2.0	NA
Vishnu Chemicals	1:5	10.0	2.0	NA
Lancer Containe.	1:2	10.0	5.0	NA
Star Housing Fin	1:2	10.0	5.0	NA
Rajnandini Metal	1:10	10.0	1.0	30-11-2022
Easy Trip Plann.	1:2	2.0	1.0	NA
Likhitha Infra.	1:2	10.0	5.0	NA

Source: Capitaline, ICICI Direct Research

Bonus issue			
Company name	Ratio	Ex-bonus date	Record date
GPT Infraproject	1:1	11-11-2022	12-11-2022
FSN E-Commerce	5:1	10-11-2022	11-11-2022
Modi's Navnirman	3:1	15-11-2022	15-11-2022







Major	Major stakeholder's activity in October 2022				
Company	No of shares Bought/Sold (In lakhs)	Total Equity (In lakhs)	Net change % of total (%)		
CSB Bank	31.0	1734.9	1.8		
Fortis Health.	9.1	7549.6	0.1		
Motil.Oswal.Fin.	6.2	1476.4	0.4		
KEI Industries	-2.7	901.9	-0.3		
Power Fin.Corpn.	-548.0	26400.8	-2.1		
K P R Mill Ltd	-70.0	3418.1	-2.0		
Angel One	-1.2	833.2	-0.1		

Source: Capitaline, ICICI Direct Research

Key Highlights

- ❖SBI Funds Management purchased 31.0 lakh shares (1.8%) of CSB Bank
- ❖Aditya Birla Sun Life Mutual Fund purchased 9.1 lakh shares (0.12%) of Fortis Health.
- ❖PPFAS Mutual Fund purchased 6.2 lakh shares (0.4%) of Motilal Oswal Fin.
- ❖Anil Gupta & PACs sold 2.7 lakh shares (0.3%) of KEI Industries
- ❖HDFC Mutual Fund sold 548.0 lakh shares (2.1%) of Power Fin. Corpn.
- ❖L & T Mutual Fund sold 70 lakh shares (2.0%) of KPR Mills
- ❖International Finance Corporation sold 1.2 lakh shares (0.14%) of Angel One



Preferential allotment in October 2022



On a month on month (MoM) basis, the momentum related to raising money (in terms of number of companies) through preferential allotment declined in October 2022. Total 11 companies raised capital through the preferential allotment route in October 2022 compared to 20 companies in September 2022. Anupam Rasayan, Moschip Tech, Ansal Properties, Fredun Pharma and Refex Industries were among major companies that raised capital through preferential allotment in October 2022. Overall, preferential allotment declined as a funding route over CY17-19. For full year CY18, 223 companies had raised capital through preferential allotment compared to 243 companies in CY17 and 142 companies for CY19. For CY20, 156 companies raised capital through preferential allotment. In CY21 preferential allotment gained traction as 264 companies raised capital through preferential allotment. For YTDCY22 (up to October 2022), 144 companies have raised capital through preferential allotment.

Preferential allotment in October 2022						
Company	No.of Eq. Shares Face Value Issue Price			Issued To	Issued Category	Date of allotment
	(in crore)	(₹)	(₹)			
Ansal Properties	1.7	5.0	22.0	NA	Non Promoter	19-10-2022
Fredun Pharma	0.0	10.0	996.2	Amitava Chatterjee & PACs	Promoter & Non-Promoter	15-10-2022
Moschip Tech.	0.3	2.0	61.1	M/s. Mayuka Holdings Pvt Ltd	Promoter	18-10-2022
Prismx Global	3.5	1.0	6.0	Wassup Media Private Limited & PACs	Non-Promoter	22-10-2022
Refex Industries	0.1	10.0	130.0	SunEdison Energy India Pvt. Ltd.	Promoter Group	07-10-2022
Anupam Rasayan	0.7	10.0	725.0	NA	QIBs	04-10-2022
Servotech Power	0.3	10.0	93.0	Zenith Multi Trading DMCC & PACs	NA	15-10-2022




Historical trend of rights and bonus issues



Number of rights issues- CNX 500



Number of bonus issues- CNX 500




Key Highlights

- ❖ Of the CNX 500 companies, three used the rights issue method to raise capital in CY21 compared to nine in CY20
- ❖ Total 13 companies had announced bonus issue in CY21 compared to five in CY20


Historical trend of stock splits and dividend payouts



Number of stock splits- CNX 500



Average dividend payout ratio (%) for CNX 500



Key Highlights

- ❖ Nine companies had announced a stock split in CY21 compared to seven in CY20
- ❖ Average dividend payout ratio declined to 38.3% in FY22





Pankaj Pandey Head – Research pankaj.pandey@icicisecurities.com

ICICI Direct Research Desk,

ICICI Securities Limited,

1st Floor, Akruti Trade Centre,

Road no.7, MIDC

Andheri (East)

Mumbai – 400 093

research@icicidirect.com

Disclaimer



ANALYST CERTIFICATION

I/We, Raj Deepak Singh B.E, MBA (Finance), Bharat Chhoda, MBA, Cheragh Sidhwa, MBA, Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products.

ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager and Research Analyst. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number – INH000000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com.

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Retail Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Institutional Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or comanaging public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as a entity are engaged in various financial service businesses, they might have financial interests or actual/ beneficial ownership of one percent or more or other material conflict of interest various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.